PCSK9-targeted therapies

PCSK9-targeted therapies has been studied in 4 papers since 2026: 3 observational studies in people, 1 review; 4 in the past year. The newest paper, Nov 2, 2026: “Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab”.

Intervention

4 papers study it9 findingsUpdated

3 new papers in 30 daysSee all 4 papers on PCSK9-targeted therapies

At a glance

The findings reach people, from one lab or study. 3 independent labs in 2 countries.

“PCSK9-targeted therapy significantly reduced the risk of all-cause stroke (OR, 0.78 (95% CI: 0.68-0.90), P < 0.001)”
Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trialsThe American journal of medicine2026doi:10.1016/j.amjmed.2026.06.034

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 2 countries
  • Humans3

Studies in people

1 study gave PCSK9-targeted therapies to people and measured what changed.

What changedDesignPeopleSource

down: Lowers the risk of strokeOR 0.78 (95% CI 0.68-0.90)

down: Lowers the risk of ischemic strokeOR 0.77 (95% CI 0.63-0.94)

no change: Has no effect on hemorrhagic strokeOR 1.16 (95% CI 0.70-1.93)

Review of trials64,116 people pooledThe American journal of medicine, Aug 4, 2026

What did studies of PCSK9-targeted therapies find?

3

Studies of PCSK9-targeted therapies measured 3 outcomes: Parkinson's disease, dementia and hemorrhagic stroke.

Parkinson's disease

no changein humans1OR 0.82

1 study
  1. PCSK9-targeted therapies showed no clear effect on Parkinson's disease in humans (OR 0.82 (95% CI 0.11-6.37)).

    “no significant association was observed for the risk of dementia and Parkinson's disease”

    Human trialn = 64,116

    Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials

    The American journal of medicine

More on Parkinson's disease

Dementia

no changein humans1OR 0.77

1 study
  1. PCSK9-targeted therapies showed no clear effect on dementia in humans (OR 0.77 (95% CI 0.14-4.28)).

    “no significant association was observed for the risk of dementia and Parkinson's disease”

    Human trialn = 64,116

    Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials

    The American journal of medicine

More on Dementia

Hemorrhagic stroke

no changein humans1OR 1.16

1 study
  1. PCSK9-targeted therapies showed no clear effect on hemorrhagic stroke in humans (OR 1.16 (95% CI 0.70-1.93)).

    “no significant association was observed for the risk of hemorrhagic stroke (OR, 1.16 (95%CI: 0.70-1.93), P = 0.56)”

    Human trialn = 64,116

    Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials

    The American journal of medicine

More on Hemorrhagic stroke

What is PCSK9-targeted therapies linked with?

6

Studies link PCSK9-targeted therapies with 6 measures, among them acute myocardial infarction, mortality and major adverse cardiovascular events.

Acute myocardial infarction

mixedin humans1

1 study
  1. PCSK9-targeted therapies are associated with acute myocardial infarction in humans (Atherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use).

    “AMI was lower at 1 year but not consistently thereafter.”

    HumansAtherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use1, 3, and 5 years

    Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab

    AHA Scientific Sessions 2026 abstract

More on Acute myocardial infarction

Mortality

downin humans1HR 0.323

1 study
  1. PCSK9-targeted therapies are associated with mortality in humans (1 year: HR 0.323 (95% CI 0.305–0.341); 3 years: HR 0.432 (0.416–0.448); 5 years: HR 0.467 (0.451–0.483)).

    “All-cause mortality was lower at 1 year (HR 0.323, 95% CI 0.305-0.341)”

    HumansAtherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use; possible residual confounding1, 3, and 5 years

    Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab

    AHA Scientific Sessions 2026 abstract

Major adverse cardiovascular events

downin humans1HR 0.857

1 study
  1. PCSK9-targeted therapies are associated with major adverse cardiovascular events in humans (Atherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use) (1 year: HR 0.857 (95% CI 0.837–0.878); 3 years: HR 0.946 (0.927–0.965); 5 years: HR 0.969 (0.950–0.989)).

    “After matching, PCSK9 therapy was associated with significantly lower MACE at 1 year”

    HumansAtherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use1, 3, and 5 years

    Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab

    AHA Scientific Sessions 2026 abstract

LDL cholesterol

downin humans1−48% average ldl-c reduction

1 study
  1. PCSK9-targeted therapies are associated with LDL cholesterol in humans (PCSK9-targeted treatment with background oral lipid-lowering therapy) (-48% average LDL-c reduction).

    “While the average LDL-c reduction was -48% across the entire cohort, results differed widely according to adherence”

    HumansPCSK9-targeted treatment with background oral lipid-lowering therapyMedian 15 months70% malesn = 403

    Perceived effectiveness of PCSK9i-SiRNA therapy and adherence to background statin therapy: real-world analysis of the DAMAGE registry

    ESC Congress 2026 abstract

More on LDL cholesterol

Ischemic stroke

downin humans1OR 0.77

1 study
  1. PCSK9-targeted therapies lower the risk of ischemic stroke in humans (OR 0.77 (95% CI 0.63-0.94)).

    “PCSK9-targeted therapy significantly reduced the risk of all-cause stroke (OR, 0.78 (95% CI: 0.68-0.90), P < 0.001) and ischemic stroke (OR, 0.77 (95% CI: 0.63-0.94), P = 0.01)”

    Human trialn = 64,116

    Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials

    The American journal of medicine

More on Ischemic stroke

Stroke

downin humans1OR 0.78

1 study
  1. PCSK9-targeted therapies lower the risk of stroke in humans (OR 0.78 (95% CI 0.68-0.90)).

    “PCSK9-targeted therapy significantly reduced the risk of all-cause stroke (OR, 0.78 (95% CI: 0.68-0.90), P < 0.001)”

    Human trialn = 64,116

    Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials

    The American journal of medicine

More on Stroke

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 2Nov 2026: 14 papers in 12 months